Essex Woodlands Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Essex Woodlands Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-457,085	Closed	-$1.39M	–	7
2024 Q4	$1.39M	Hold	457,085	–	–	0.32%	6
2024 Q3	$2.37M	Hold	457,085	–	–	0.68%	5
2024 Q2	$1.17M	Hold	457,085	–	–	0.38%	6
2024 Q1	$2.25M	Hold	457,085	–	–	0.65%	5
2023 Q4	$4.02M	Hold	457,085	–	–	0.99%	5
2023 Q3	$5.24M	Hold	457,085	–	–	4.62%	4
2023 Q2	$11.6M	Hold	457,085	–	–	8.76%	4
2023 Q1	$14.7M	Hold	457,085	–	–	8.52%	3
2022 Q4	$8.44M	Hold	457,085	–	–	4.7%	6
2022 Q3	$12.3M	Hold	457,085	–	–	5.1%	5
2022 Q2	$6.32M	Hold	457,085	–	–	2.61%	6
2022 Q1	$8.91M	Hold	457,085	–	–	2.15%	6
2021 Q4	$7.46M	Sell	457,085 -15,505	-3%	-$258K	1.68%	7
2021 Q3	$13.2M	Sell	472,590 -861,102	-65%	-$24.6M	2.92%	7
2021 Q2	$37.3M	Sell	1,333,692 -1,426,258	-52%	-$41.1M	5.51%	5
2021 Q1	$77.1M	Sell	2,759,950 -582,097	-17%	-$16.1M	12.06%	3
2020 Q4	$94.7M	Hold	3,342,047	–	–	24.58%	2
2020 Q3	$84M	Hold	3,342,047	–	–	44.64%	1
2020 Q2	$81.6M	Hold	3,342,047	–	–	40.04%	1
2020 Q1	$49.5M	Hold	3,342,047	–	–	31.84%	1
2019 Q4	$54.2M	Hold	3,342,047	–	–	25.3%	2
2019 Q3	$43.4M	Hold	3,342,047	–	–	27.06%	2
2019 Q2	$43.3M	Hold	3,342,047	–	–	24.99%	3
2019 Q1	$52.7M	Hold	3,342,047	–	–	26.22%	3
2018 Q4	$91.7M	Hold	3,342,047	–	–	36.54%	1
2018 Q3	$83M	Hold	3,342,047	–	–	17.27%	4
2018 Q2	$91.7M	Sell	3,342,047 -500,000	-13%	-$15M	21.3%	2
2018 Q1	$118M	Hold	3,842,047	–	–	25.9%	2
2017 Q4	$137M	Sell	3,842,047 -750,000	-16%	-$21.5M	24.83%	1
2017 Q3	$127M	Hold	4,592,047	–	–	22.44%	2
2017 Q2	$121M	Hold	4,592,047	–	–	21.92%	2
2017 Q1	$95.5M	Hold	4,592,047	–	–	21.79%	2
2016 Q4	$95.1M	Hold	4,592,047	–	–	21.68%	2
2016 Q3	$74.4M	Hold	4,592,047	–	–	15.49%	3
2016 Q2	$62.5M	Hold	4,592,047	–	–	15.74%	3
2016 Q1	$80.2M	Hold	4,592,047	–	–	20.98%	2
2015 Q4	$157M	Hold	4,592,047	–	–	28.69%	2
2015 Q3	$137M	Hold	4,592,047	–	–	24.98%	2
2015 Q2	$147M	Hold	4,592,047	–	–	26.51%	1
2015 Q1	$95.2M	Hold	4,592,047	–	–	18.88%	2
2014 Q4	$77.8M	Hold	4,592,047	–	–	24.28%	2
2014 Q3	$88.8M	Hold	4,592,047	–	–	32.32%	1
2014 Q2	$156M	Hold	4,592,047	–	–	32.47%	1
2014 Q1	$145M	Buy	+4,592,047	New	+$143M	36.82%	1

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Essex Woodlands Management's RVNC Position: Q1 2025 in Review

Essex Woodlands Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 457,085 shares — an estimated $1.39M sold.

Essex Woodlands Management first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $157M in Q4 2015. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Essex Woodlands Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Essex Woodlands Management sold 457,085 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.39M.
Essex Woodlands Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
Essex Woodlands Management's Revance Therapeutics, Inc. position peaked at $157M in Q4 2015.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Essex Woodlands Management's 13F filing for Q1 2025, filed 13 May 2025.